Compliance with treatment in osteoporosis patients: An ongoing problem

Australian Family Physician

Volumn 35, Issue 3, 2006, Pages 135-137

  Sambrook, Philip ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT;

ARTICLE; AUSTRALIA; DRUG ADMINISTRATION; FEMALE; HUMAN; OSTEOPOROSIS; PSYCHOLOGICAL ASPECT; STATISTICS; TREATMENT REFUSAL;

AUSTRALIA; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; OSTEOPOROSIS; TREATMENT REFUSAL;

EID: 33646437957     PISSN: 03008495     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Yasin S. Detecting and improving compliance: is concordance the solution?. Aust Fam Physician 1998;27:255-60.
2. Hughes CM. Medication non-adherence in the elderly: how big is the problem?. Drugs Aging 2004;21:793-811.
3. Wahl C, Gregoire J-P, Teo K, et al. Concordance, compliance and adherence in healthcare: closing gaps and improving outcomes. Healthc Q 2005;8:65-70.
4. Schaffer S, Yoon S-JL. Evidence based methods to enhance medication adherence. Nurse Pract 2001;26:44,50,52,54.
5. Chapman RH, Benner JS, Petrilla AA, et al. Predictors of adherence with antihypertensive and lipid lowering therapy. Arch Intern Med 2005;165:1147-52.
6. The burden of brittle bones: costing osteoporosis in Australia. Canberra: Access Economics, 2001.
7. O'Neill S, MacLennan A, Bass S, et al. Guidelines for the management of postmenopausal osteoporosis. Aust Fam Physician 2004;33:910-8.
8. Caro JJ, Ishak KJ, Huybrechts KF, et al. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 2004;15:1003-8.
9. Calcino G. Osteoporosis survival curve analysis. HI Connections Pty Ltd, May 2005.
10. Bartl R, Goette S, Hadji P, et al. Persistence and compliance with daily and weekly administered bisphosphonates for osteoporosis in Germany. Osteoporos Int 2005;16(Suppl 3):195.
11. Recker RR, Gallagher R, Amonkar M, et al. Medication persistence is better with weekly bisphosphonates, but remains suboptimal. J Bone Miner Res 19(Suppl 1): SA407.
12. Van Staa TP, Geusens P, Leufkens HGM, Cooper C. Persistence to bisphosphonate treatment in actual clinical practice. Bone 2005;36:610.
13. IMS, API/AHI Data MAT December 2004.
14. Tosteson ANA, Grove MR, Hammond CS, et al. Early discontinuation of treatment for osteoporosis. Am J Med 2003;115:209-16.
15. Schimmer RC, Bauss F. Effect of daily and intermittent use of ibandronate on bone mass and bone turnover in postmenopausal osteoporosis: a review of three phase II studies. Clin Ther 2003;25:19-34.
16. Cramer JA, Amonkar MM, Hebborn A, et al. Does dosing regimen impact persistence with bisphosphonate therapy among postmenopausal osteoporotic women?. J Bone Mineral Res 19(Suppl 1):M434.
17. Simon JA, Lewiecki EM, Smith ME, et al. Patient preference for once weekly alendronate 70 mg versus once daily alendronate 10 mg: a multicenter, randomised, open-label, crossover study. Clin Ther 2002;24:1871-85.
18. Chesnut III CH, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19:12419.
19. Miller PD, McClung MR, Macovei L, et al. Monthly oral ibandronate in postmenopausal osteoporosis: 1 year results from the MOBILE study. J Bone Miner Res 2005;20:1315-22.
20. Akesson K, Beusterien K, Hebborn A, et al. Patient preference for once monthly over weekly bisphosphonate treatment. Osteoporos Int 2005;16(Suppl 3):315.
21. Reid IR, Brown JP, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002;346:2088-9.
22. Colon-Emeric S, Caminis J, Suh TT, et al. The HORIZON recurrent fracture trial: design of a clinical trial in the prevention of subsequent fractures after low trauma hip fracture repair. Curr Med Res Opin 2004;20:903-10.